Inhibrx Biosciences, Inc. Annual Report - How They Did This Year

Hey there! Thinking about investing in Inhibrx Biosciences, Inc.? This guide breaks down their past year. We use plain English to help you decide if it's a good fit. We'll cover the important stuff without confusing financial jargon.

First off, Inhibrx Biosciences, Inc. (you'll see them as INBX on the Nasdaq Global Market) finds, develops, and aims to sell new biologic medicines. They develop potential new medicines. This involves early research and human trials. Their goal is to bring new treatments to patients. This report covers their performance for the year ending December 31, 2025.

It's important to know that Inhibrx is considered a "smaller reporting company" and an "emerging growth company." As a Smaller Reporting Company (SRC), Inhibrx follows fewer reporting rules. For example, they show fewer years of financial results. They also share less detail about executive pay than larger companies.

They are also an Emerging Growth Company (EGC). This status is for companies with less than $1.235 billion in total yearly sales. It gives Inhibrx fewer reporting duties under federal securities laws. For example, outside auditors don't have to check their internal financial controls. They also get more time to adopt new accounting rules.

However, they chose to adopt new accounting rules faster. This means they did not use the extra time available to EGCs. This shows they apply new accounting standards like larger companies. It signals transparency and a proactive approach. This generally means they're still in earlier stages compared to giant corporations. This can come with both higher risks and potentially higher rewards.

To give you a quick idea of their size, as of June 30, 2025, the market valued the company at about $174.6 million. This market value puts Inhibrx firmly in the small-cap biotech category. This is typical for a company still developing products. They had around 14.6 million shares available to trade as of March 11, 2026.

As an emerging growth company focused on research, Inhibrx typically generates minimal or no product sales. They fund operations mainly by raising money, not selling products. So, the company likely lost money. They invested heavily in developing new medicines.

Like many biotech companies, their future depends on many unknowns. This includes how their research goes, if new treatments get approved, and if they can successfully sell them. This involves significant inherent risks for investors.

Research and development programs often fail. Many potential drugs stop early. This happens due to not working, safety issues, or production problems. Even if a potential drug finishes human trials, approval is not guaranteed. Agencies like the FDA must approve it. This process is long, complex, and changes often.

Approval does not guarantee sales success. Success depends on market acceptance and competition. It also depends on pricing, insurance coverage, and their ability to make and deliver products.

Developing these products costs a lot of money. They need to raise more money on good terms. This might involve selling more shares. That could reduce your ownership percentage. This is an ongoing concern.

Remember, a big part of their story is still being written. It involves many future plans and potential hurdles.